ClinicalTrials.gov recorded primary completion on 13 July 2026 for a Phase 3 study of EYP-1901 in wet age-related macular degeneration. The randomized, double-masked LUGANO trial enrolled 400 participants and compared EYP-1901 with aflibercept 2.0 mg.
Background
EYP-1901 was studied in people with wet age-related macular degeneration, also called wAMD. The registry listed EYP-1901 and aflibercept 2.0 mg as the trial interventions. The supplied record did not provide additional information about EYP-1901’s drug class, mechanism, prior approvals, or the prevalence of wAMD.
Trial design
The study was identified as NCT06668064 and had a Phase 3 design. It was randomized and double-masked, with an enrollment of 400 participants. The trial’s overall status was active, not recruiting.
The study followed participants for 2 years and compared the efficacy of EYP-1901 with aflibercept. The brief title stated that primary efficacy would be determined at Week 56. The supplied record did not include primary outcome entries, outcome measurements, or statistical analyses.
What this means
The registry event documents primary completion for a late-stage comparison of EYP-1901 and aflibercept in wet age-related macular degeneration. It establishes the study’s design, enrollment, comparator, and planned Week 56 primary-efficacy assessment.
No efficacy measurements, comparative results, p-values, confidence intervals, or adverse-event summary were supplied. The record therefore does not show whether EYP-1901 met its primary endpoint, how it compared with aflibercept, or whether the study changed the drug’s clinical use.
Source
Source: ClinicalTrials.gov, registry record for “A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56,” NCT06668064, with the primary-completion event dated 13 July 2026. The record is available at clinicaltrials.gov/study/NCT06668064.